InMed 10-Q: Equity Turns Negative, $1.1M Cash Lasts Into Q4 2026
INM has more than doubled off its 52-week low of $0.575 on elevated volume (2.1× avg).
Summary
InMed ended September 2026 with $1.1 million of cash and short-term investments, enough to fund operations only into the fourth quarter of calendar 2026, and shareholders' equity turned negative at $(1.2) million. Survival now hinges on the Mentari merger and its November 4, 2026 shareholder vote.
Key Events · Earnings and Guidance · INM
-
Cash Falls to $1.1 Million
Cash and cash equivalents dropped to $1,094,488 at September 30, 2026 from $2,194,413 at June 30, 2026; including $40,331 of short-term investments, total liquidity of $1.1 million funds operations only into the fourth quarter of calendar 2026.
-
Shareholders' Equity Turns Negative
Total shareholders' equity was $(1,199,396) at September 30, 2026 versus $1,075,007 at June 30, 2026 — the same equity measure that triggered the September 18, 2026 Nasdaq notice for falling below the $2,500,000 minimum.
-
Going Concern Doubt Restated
Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year of issuance, with an accumulated deficit of $132.6 million and a $2,330,778 net loss for the quarter.
-
BayMedica Creditor Assignment
BayMedica engaged Pashman Stein Walder Hayden P.C. on October 2, 2026 for a potential Delaware assignment for the benefit of creditors; InMed, its largest secured creditor, does not currently expect to receive any proceeds.
Analysis · INM · Life Sciences
InMed's fiscal Q1 shows the company running out of financial room before its rescue. Cash and equivalents fell to $1.09 million from $2.19 million in the quarter, and total cash, equivalents and short-term investments of $1.1 million only fund operations into the fourth quarter of calendar 2026 — the company states substantial doubt about its ability to continue as a going concern. Shareholders' equity flipped to negative $1.2 million, which is the very metric behind the September 18 Nasdaq notice, so the compliance plan filed October 30 now rests almost entirely on the Mentari merger closing. That deal would hand pre-merger InMed holders roughly 0.97% of the combined company, and the November 4, 2026 shareholder vote is the gate. Separately, BayMedica engaged counsel on October 2 for a potential Delaware assignment for the benefit of creditors, and InMed — its largest secured creditor — does not expect to recover anything. The quarter's $2.33 million net loss was driven by $1.80 million of G&A, up 46% on merger transaction costs, while R&D fell 64% to $0.21 million as programs were effectively frozen.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.58 to $2.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.